The relationship between CKD, cardiovascular disease, and diabetes is well documented.1-4 We know that CKD greatly amplifies the risks associated with hypertension, particularly in the diabetic patient. Therefore, the earlier these conditions are monitored the better for your patients....

Did you Know
  • Early CKD detection and treatment of anemia can help lower cardiovascular risks and progression to kidney failure
  • Timely identification and achievement of blood pressure goals may improve CKD outcomes2
Know the Facts
  • Over 26 million US adults have CKD and millions more are at risk3
  • CKD is the 9th leading cause of death in America1
  • The most common causes of CKD are hypertension and diabetes
  • Heart disease and infection are the leading causes of death in CKD patients
Risk Factors
  • High risk groups include patients with diabetes, hypertension, and family history of kidney disease
  • CKD is more prevalent among the elderly and African Americans, Hispanics, Pacific Islanders, and Native Americans4
Comorbidity Correlation
  • Diabetes and hypertension are the two leading risk factors for CKD
  • Obesity, specifically waist-to-hip (WHR) ratio, is associated with cardiac events in patients with CKD5
Multidisciplinary Approach
Help ensure successful prevention and control of CKD:
  • Screen patients for hypertension
  • Test and diagnose predisposing comorbidities
  • Treat all stages of CKD aggressively to guideline goals, including anemia
American Regent. Enriching the lives of anemia patients. ™

IMPORTANT SAFETY INFORMATION: Venofer® (iron sucrose injection, USP) is contraindicated in patients with evidence of iron overload, in patients with known hypersensitivity to VenoferŪ or any of its inactive components, and in patients with anemia not caused by iron deficiency. Serious hypersensitivity reactions have been reported in patients receiving VenoferŪ. In clinical studies, several patients experienced hypersensitivity reactions presenting with wheezing, dyspnea, hypotension, rashes, or pruritus. The post-marketing spontaneous reporting system includes reports of patients who experienced serious or life-threatening reactions (anaphylactic shock, loss of consciousness or collapse, bronchospasm with dyspnea, or convulsion) associated with VenoferŪ administration.

Hypotension has been reported frequently in non-dialysis dependent-CKD patients receiving IV iron. Hypotension following administration of VenoferŪ may be related to rate of administration and total dose delivered.

In a multi-dose efficacy study in non-dialysis dependent-CKD patients (N=91), the most frequent adverse events (≥5%) whether or not related to VenoferŪ administration, were taste disturbance (7.7%), peripheral edema (7.7%), diarrhea (5.5%), constipation (5.5%), nausea (5.5%), dizziness (5.5%), and hypertension (5.5%). In an additional study of VenoferŪ with varying erythropoietin doses in 96 treated NDD-CKD patients, adverse events, whether or not related to VenoferŪ reported by ≥5% of VenoferŪ exposed patients are as follows: diarrhea (16.5%), edema (16.5%), nausea (13.2%), vomiting (12.1%), arthralgia (7.7%), back pain (7.7%), headache (7.7%), hypertension (7.7%), taste disturbance (7.7%), dizziness (6.6%), extremity pain (5.5%), and injection site burning (5.5%).

In multi-dose efficacy studies in HDD-CKD patients (N=231), the most frequent adverse events (> 5%) whether or not related to VenoferŪ administration, were hypotension (39.4%), muscle cramps (29.4%), nausea (14.7%), headache (12.6%), graft complications (9.5%), vomiting (9.1%), dizziness (6.5%) hypertension (6.5%), chest pain (6.1%), and diarrhea (5.2%). In post-marketing safety studies in HDD-CKD patients (N=1051), the most frequent adverse events reported (>1%), whether or not related to VenoferŪ administration, were congestive heart failure, sepsis, and taste disturbance. In the study of PDD-CKD patients (N=75), the most frequent adverse events, whether or not related to VenoferŪ, reported by ≥5% of these patients were diarrhea (8.0%), peritoneal infection (8.0%) vomiting (8.0%), hypertension (8.0%), pharyngitis (6.7%), peripheral edema (5.3%), and nausea (5.3%).


Please see Full Prescribing Information.


References